ICU Medical (ICUI) Financials

$130.44 +1.45 (+1.12%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$130.36 -0.08 (-0.06%)

As of 05/27/2025 04:20 PM Eastern

Annual Income Statements for ICU Medical

This table shows ICU Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-118	-30	-74	103	87	101	29	69	63	45
Consolidated Net Income / (Loss)	-118	-30	-74	103	87	101	29	69	63	45
Net Income / (Loss) Continuing Operations	-118	-30	-74	103	87	101	29	69	63	45
Total Pre-Tax Income	-66	-78	-114	123	97	115	22	51	85	70
Total Operating Income	43	23	-43	123	98	107	30	-13	83	69
Total Gross Profit	825	740	698	491	461	472	570	426	201	181
Total Revenue	2,382	2,259	2,280	1,316	1,271	1,266	1,400	1,293	379	342
Operating Revenue	2,382	2,259	2,280	1,316	1,271	1,266	1,400	1,293	379	341
Total Cost of Revenue	1,557	1,519	1,582	825	810	794	830	867	178	161
Operating Cost of Revenue	1,557	1,519	1,582	825	810	794	830	867	178	161
Total Operating Expenses	782	717	741	368	363	365	540	439	118	112
Selling, General & Admin Expense	639	607	608	303	284	277	320	302	89	83
Research & Development Expense	89	85	93	47	43	49	53	51	13	16
Restructuring Charge	60	41	71	18	28	81	105	78	15	8.45
Other Special Charges / (Income)	-5.40	-16	-32	0.00	9.00	-47	20	8.00	0.00	-1.09
Total Other Income / (Expense), net	-109	-101	-72	-0.06	-0.67	7.35	-7.38	65	2.22	1.13
Interest Expense	96	95	66	-1.98	-1.92	0.55	0.71	2.05	0.12	0.04
Other Income / (Expense), net	-13	-5.91	-5.14	-2.04	-2.59	7.90	-6.67	67	2.34	1.17
Income Tax Expense	52	-49	-40	20	11	14	-6.42	-17	22	25
Basic Earnings per Share	($4.83)	($1.23)	($3.11)	$4.86	$4.16	$4.90	$1.41	$3.50	$3.90	$2.84
Weighted Average Basic Shares Outstanding	24.39M	24.09M	23.87M	21.21M	20.91M	20.63M	20.39M	19.61M	16.17M	15.85M
Diluted Earnings per Share	($4.83)	($1.23)	($3.11)	$4.74	$4.02	$4.69	$1.33	$3.29	$3.66	$2.73
Weighted Average Diluted Shares Outstanding	24.39M	24.09M	23.87M	21.78M	21.59M	21.55M	21.60M	20.86M	17.25M	16.50M
Weighted Average Basic & Diluted Shares Outstanding	24.52M	24.14M	24.00M	23.79M	21.14M	20.77M	20.40M	19.60M	16.20M	15.80M

This table shows ICU Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-15	-24	-33	-21	-39	-17	7.24	-9.93	-9.81	-16	-13
Consolidated Net Income / (Loss)	-15	-24	-33	-21	-39	-17	7.24	-9.93	-9.81	-16	-13
Net Income / (Loss) Continuing Operations	-15	-24	-33	-21	-39	-17	7.24	-9.93	-9.81	-16	-13
Total Pre-Tax Income	-11	8.22	-18	-20	-37	-37	-5.37	-23	-13	-21	-21
Total Operating Income	13	38	8.24	7.69	-11	-12	23	2.76	9.40	-0.22	-0.47
Total Gross Profit	210	227	205	207	185	172	184	192	192	175	186
Total Revenue	605	630	589	596	567	588	553	549	569	578	598
Operating Revenue	605	630	589	596	567	588	553	549	569	578	598
Total Cost of Revenue	395	403	384	389	381	416	369	357	377	403	411
Operating Cost of Revenue	395	403	384	389	381	416	369	357	377	403	411
Total Operating Expenses	197	190	197	200	196	184	161	190	183	175	187
Selling, General & Admin Expense	157	159	163	160	158	155	149	151	153	143	153
Research & Development Expense	23	22	21	23	22	22	21	22	20	23	23
Restructuring Charge	17	9.77	17	17	16	11	7.16	12	11	9.63	14
Other Special Charges / (Income)	0.00	-1.41	-3.95	-0.34	0.30	-3.99	-16	4.02	-0.70	-0.84	-4.06
Total Other Income / (Expense), net	-24	-29	-26	-27	-26	-24	-28	-26	-23	-21	-21
Interest Expense	22	23	25	24	24	24	24	24	23	20	18
Other Income / (Expense), net	-1.76	-6.02	-1.48	-3.38	-2.34	-0.09	-4.04	-1.50	-0.27	-1.15	-3.03
Income Tax Expense	4.57	32	15	1.87	2.70	-20	-13	-13	-3.58	-5.91	-8.10
Basic Earnings per Share	($0.63)	($0.97)	($1.35)	($0.88)	($1.63)	($0.71)	$0.30	($0.41)	($0.41)	($0.64)	($0.55)
Weighted Average Basic Shares Outstanding	24.54M	24.39M	24.44M	24.39M	24.22M	24.09M	24.13M	24.08M	24.01M	23.87M	23.91M
Diluted Earnings per Share	($0.63)	($0.97)	($1.35)	($0.88)	($1.63)	($0.71)	$0.30	($0.41)	($0.41)	($0.64)	($0.55)
Weighted Average Diluted Shares Outstanding	24.54M	24.39M	24.44M	24.39M	24.22M	24.09M	24.37M	24.08M	24.01M	23.87M	23.91M
Weighted Average Basic & Diluted Shares Outstanding	24.61M	24.52M	24.48M	24.43M	24.37M	24.14M	24.14M	24.14M	24.06M	24.00M	23.98M

This table details how cash moves in and out of ICU Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	54	45	-344	157	127	-76	55	-155	109	60
Net Cash From Operating Activities	204	166	-62	268	223	102	160	154	90	64
Net Cash From Continuing Operating Activities	204	166	-62	268	223	102	160	154	90	64
Net Income / (Loss) Continuing Operations	-118	-30	-74	103	87	101	29	69	63	45
Consolidated Net Income / (Loss)	-118	-30	-74	103	87	101	29	69	63	45
Depreciation Expense	220	229	235	90	86	77	75	67	19	18
Amortization Expense	28	29	57	10	9.74	0.42	0.63	0.15	1.36	1.67
Non-Cash Adjustments To Reconcile Net Income	75	82	56	47	42	82	65	-40	15	16
Changes in Operating Assets and Liabilities, net	-0.58	-144	-336	18	-1.03	-159	-8.46	59	-8.68	-16
Net Cash From Investing Activities	-89	-88	-1,909	-91	-98	-167	-103	-267	16	-11
Net Cash From Continuing Investing Activities	-89	-88	-1,909	-91	-98	-167	-103	-267	16	-11
Purchase of Property, Plant & Equipment	-79	-84	-90	-69	-92	-97	-93	-74	-23	-13
Acquisitions	-11	-9.78	-1,853	-30	-8.39	-85	-9.36	-168	-3.78	-58
Purchase of Investments	0.00	0.00	-3.40	-10	-33	-26	-30	-25	-118	-56
Sale of Property, Plant & Equipment	0.75	1.50	0.99	0.22	6.18	0.03	14	0.00	3.27	3.59
Sale and/or Maturity of Investments	0.50	4.22	36	18	29	41	15	0.00	159	83
Net Cash From Financing Activities	-56	-36	1,637	-17	-0.04	-11	8.02	-44	2.47	16
Net Cash From Continuing Financing Activities	-56	-36	1,637	-17	-0.04	-11	8.02	106	2.47	16
Repayment of Debt	-51	-30	-25	0.00	-150	0.00	0.00	-75	0.00	0.00
Repurchase of Common Equity	-12	-9.35	-11	-8.34	-13	-19	-6.25	-4.06	-17	-1.52
Issuance of Debt	0.00	0.00	1,664	0.00	150	0.00	0.00	-	-	-
Other Financing Activities, net	7.19	3.06	8.11	-8.54	13	7.73	14	32	17	15
Effect of Exchange Rate Changes	-4.93	3.16	-9.48	-3.25	2.85	-0.23	-10	1.79	0.22	-8.28
Cash Interest Paid	100	96	64	0.86	1.75	0.55	0.71	2.05	0.12	0.04
Cash Income Taxes Paid	25	36	28	20	32	9.68	13	5.11	21	23

This table details how cash moves in and out of ICU Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-19	-3.95	9.86	51	-2.80	57	1.31	-25	12	-35	-12
Net Cash From Operating Activities	51	40	36	82	46	91	35	-1.47	41	-1.71	2.31
Net Cash From Continuing Operating Activities	51	40	36	82	46	91	35	-1.47	41	-1.71	2.31
Net Income / (Loss) Continuing Operations	-15	-24	-33	-21	-39	-17	7.24	-9.93	-9.81	-16	-13
Consolidated Net Income / (Loss)	-15	-24	-33	-21	-39	-17	7.24	-9.93	-9.81	-16	-13
Depreciation Expense	49	53	56	55	56	57	58	58	56	57	59
Amortization Expense	6.18	7.03	7.18	6.89	7.05	7.07	7.14	7.16	7.36	12	8.30
Non-Cash Adjustments To Reconcile Net Income	23	16	24	17	18	26	16	22	18	16	16
Changes in Operating Assets and Liabilities, net	-12	-12	-17	24	4.40	18	-53	-78	-31	-71	-67
Net Cash From Investing Activities	-17	-27	-23	-22	-18	-31	-25	-18	-15	-24	-13
Net Cash From Continuing Investing Activities	-17	-27	-23	-22	-18	-31	-25	-18	-15	-24	-13
Purchase of Property, Plant & Equipment	-15	-24	-20	-19	-16	-30	-21	-18	-14	-22	-21
Acquisitions	-2.23	-2.52	-2.95	-2.41	-2.95	-2.04	-3.09	-2.12	-2.53	-2.46	-2.12
Sale of Property, Plant & Equipment	0.04	0.05	0.00	0.19	0.51	0.02	0.05	1.38	0.05	0.06	0.03
Sale and/or Maturity of Investments	0.00	-	-	-	0.50	1.30	-	1.42	1.50	-	10
Net Cash From Financing Activities	-56	-8.19	-10	-10	-27	-7.85	-6.40	-5.90	-16	-10	2.53
Net Cash From Continuing Financing Activities	-56	-8.19	-10	-10	-27	-7.85	-6.40	-5.90	-16	-10	2.53
Repayment of Debt	-48	-13	-13	-13	-13	-7.44	-7.44	-7.44	-7.38	-2.45	-2.13
Other Financing Activities, net	-8.59	17	2.37	2.37	-14	8.94	1.04	1.54	-8.46	11	4.66
Effect of Exchange Rate Changes	2.96	-9.40	7.01	1.35	-3.88	4.26	-2.95	-0.08	1.94	1.00	-4.13

This table presents ICU Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	4,204	4,378	4,516	1,881	1,764	1,692	1,585	1,497	705	627
Total Current Assets	1,442	1,221	1,235	1,030	921	882	927	865	569	505
Restricted Cash	309	254	209	-	-	-	-	-	-	-
Short-Term Investments	0.00	0.50	4.22	14	15	24	37	10	0.00	41
Accounts Receivable	183	162	222	106	124	202	176	208	55	57
Inventories, net	585	709	696	290	315	338	311	289	49	44
Prepaid Expenses	70	74	89	47	41	34	46	41	7.36	7.63
Current Deferred & Refundable Income Taxes	11	22	16	20	29	16	11	11	11	14
Other Current Nonoperating Assets	284	0.00	-	-	-	-	-	-	-	-
Plant, Property, & Equipment, net	443	613	636	468	467	456	433	399	86	74
Total Noncurrent Assets	2,319	2,544	2,644	383	376	354	226	234	50	47
Goodwill	1,433	1,472	1,449	43	33	31	11	12	5.58	6.46
Intangible Assets	741	871	983	188	197	211	133	144	22	24
Noncurrent Deferred & Refundable Income Taxes	24	37	31	43	31	28	39	25	22	17
Other Noncurrent Operating Assets	121	164	180	104	102	83	40	38	0.00	-
Total Liabilities & Shareholders' Equity	4,204	4,378	4,516	1,881	1,764	1,692	1,585	1,497	705	627
Total Liabilities	2,239	2,255	2,426	265	261	315	322	299	45	47
Total Current Liabilities	556	482	495	201	195	248	249	210	41	43
Short-Term Debt	51	56	30	0.00	26	0.00	-	-	-	-
Accounts Payable	148	150	216	81	72	129	120	78	15	14
Accrued Expenses	307	268	243	118	97	118	129	132	26	29
Current Deferred & Payable Income Tax Liabilities	17	7.71	6.20	1.45	0.30	2.06	0.00	-	-	-
Other Current Nonoperating Liabilities	33	0.00	-	-	-	-	-	-	-	-
Total Noncurrent Liabilities	1,683	1,773	1,931	64	66	67	72	88	4.00	4.34
Long-Term Debt	1,532	1,578	1,624	-	-	-	21	55	1.11	1.48
Noncurrent Deferred Revenue	35	35	42	18	16	14	-	-	-	-
Noncurrent Deferred & Payable Income Tax Liabilities	49	56	126	1.49	1.66	2.09	4.46	6.08	2.89	2.86
Other Noncurrent Operating Liabilities	67	104	140	44	48	50	47	27	0.00	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,965	2,123	2,090	1,616	1,502	1,377	1,264	1,198	660	580
Total Preferred & Common Equity	1,965	2,123	2,090	1,616	1,502	1,377	1,264	1,198	660	580
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,965	2,123	2,090	1,616	1,502	1,377	1,264	1,198	660	580
Common Stock	1,415	1,369	1,334	724	695	671	660	628	164	147
Retained Earnings	690	808	838	912	809	722	621	586	517	454
Treasury Stock	-0.09	-0.26	-0.24	-0.03	-0.04	-0.16	-0.10	0.00	-0.01	0.00
Accumulated Other Comprehensive Income / (Loss)	-139	-53	-81	-19	-1.52	-15	-17	-15	-21	-21

This table presents ICU Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	4,185	4,305	4,287	4,288	4,377	4,463	4,471	4,450
Total Current Assets	1,424	1,258	1,236	1,188	1,219	1,245	1,213	1,199
Cash & Equivalents	290	313	303	251	197	196	-	-
Accounts Receivable	171	174	152	145	162	162	139	213
Inventories, net	590	692	683	693	760	775	748	625
Prepaid Expenses	75	74	81	83	84	96	87	94
Current Deferred & Refundable Income Taxes	11	5.79	18	15	15	14	14	20
Other Current Nonoperating Assets	286	-	-	-	-	-	-	-
Plant, Property, & Equipment, net	442	596	594	603	609	617	624	656
Total Noncurrent Assets	2,319	2,451	2,457	2,498	2,549	2,602	2,633	2,595
Goodwill	1,455	1,478	1,451	1,459	1,444	1,464	1,463	1,370
Intangible Assets	717	786	806	837	891	930	958	1,021
Noncurrent Deferred & Refundable Income Taxes	24	41	39	40	31	31	31	15
Other Noncurrent Operating Assets	123	147	161	162	181	176	182	187
Total Liabilities & Shareholders' Equity	4,185	4,305	4,287	4,288	4,377	4,463	4,471	4,450
Total Liabilities	2,197	2,256	2,249	2,221	2,279	2,348	2,370	2,438
Total Current Liabilities	549	550	512	455	464	484	462	489
Short-Term Debt	48	53	53	53	52	42	35	25
Accounts Payable	180	169	156	152	149	167	186	205
Accrued Expenses	279	326	300	248	251	255	235	244
Current Deferred & Payable Income Tax Liabilities	12	2.77	4.14	2.48	11	20	5.53	15
Other Current Nonoperating Liabilities	30	-	-	-	-	-	-	-
Total Noncurrent Liabilities	1,648	1,707	1,737	1,765	1,814	1,864	1,908	1,949
Long-Term Debt	1,489	1,543	1,555	1,566	1,589	1,601	1,612	1,630
Noncurrent Deferred Revenue	36	35	33	36	40	37	42	20
Noncurrent Deferred & Payable Income Tax Liabilities	45	49	54	56	78	90	115	154
Other Noncurrent Operating Liabilities	78	80	95	107	107	137	139	145
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,988	2,049	2,038	2,068	2,098	2,115	2,100	2,013
Total Preferred & Common Equity	1,988	2,049	2,038	2,068	2,098	2,115	2,100	2,013
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,988	2,049	2,038	2,068	2,098	2,115	2,100	2,013
Common Stock	1,418	1,397	1,383	1,374	1,359	1,347	1,342	1,326
Retained Earnings	675	714	747	768	825	818	828	853
Treasury Stock	-0.06	-0.21	-0.52	-4.69	-0.67	-1.61	-8.01	-0.13
Accumulated Other Comprehensive Income / (Loss)	-105	-62	-92	-70	-85	-49	-62	-166

This table displays calculated financial ratios and metrics derived from ICU Medical's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	5.44%	-0.92%	73.21%	3.56%	0.38%	-9.56%	8.31%	240.72%	11.04%	10.48%
EBITDA Growth	1.09%	12.35%	10.33%	15.95%	-0.86%	95.63%	-17.99%	13.59%	18.11%	45.67%
EBIT Growth	75.77%	135.23%	-139.63%	26.82%	-17.08%	399.31%	-56.72%	-37.47%	22.29%	75.26%
NOPAT Growth	88.23%	153.21%	-129.10%	17.97%	-7.51%	146.95%	315.20%	-128.96%	38.83%	71.29%
Net Income Growth	-296.86%	60.08%	-172.03%	18.72%	-14.02%	250.90%	-58.05%	8.81%	40.23%	70.82%
EPS Growth	-292.68%	60.45%	-165.61%	17.91%	-14.29%	252.63%	-59.57%	-10.11%	34.07%	62.50%
Operating Cash Flow Growth	22.76%	367.51%	-123.22%	20.11%	118.56%	-36.39%	3.75%	71.69%	40.11%	-3.23%
Free Cash Flow Firm Growth	1,154.03%	101.73%	-1,635.54%	143.55%	174.80%	-221.96%	109.99%	-1,601.13%	2,686.21%	-94.50%
Invested Capital Growth	-14.68%	-0.78%	238.05%	-5.49%	1.86%	20.50%	-3.79%	334.93%	6.04%	26.50%
Revenue Q/Q Growth	1.79%	0.44%	11.63%	1.55%	0.39%	-1.93%	-2.08%	26.95%	1.42%	3.17%
EBITDA Q/Q Growth	16.71%	-5.29%	9.12%	-4.73%	9.48%	21.14%	-34.54%	50.48%	1.36%	0.09%
EBIT Q/Q Growth	309.36%	-39.18%	-86.21%	-4.52%	6.16%	40.77%	-69.47%	95.89%	1.69%	0.64%
NOPAT Q/Q Growth	721.77%	-34.38%	-127.56%	-3.01%	6.69%	30.91%	-59.44%	62.82%	6.67%	-4.00%
Net Income Q/Q Growth	-6.02%	-5.74%	-91.34%	-5.69%	6.76%	38.33%	-66.46%	141.27%	6.86%	-4.07%
EPS Q/Q Growth	-5.69%	-6.03%	-99.36%	-5.77%	6.63%	38.35%	-66.50%	117.88%	5.48%	-4.55%
Operating Cash Flow Q/Q Growth	-20.02%	126.99%	-379.82%	1.55%	15.36%	-1.04%	-17.77%	69.49%	6.73%	-3.64%
Free Cash Flow Firm Q/Q Growth	167.06%	144.50%	-6.58%	32.69%	95.26%	-135.12%	-38.56%	5.98%	303.43%	-94.67%
Invested Capital Q/Q Growth	-10.32%	-1.08%	3.25%	-2.56%	1.48%	4.17%	-3.28%	-2.17%	-1.76%	16.88%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	34.62%	32.75%	30.60%	37.34%	36.31%	37.27%	40.72%	32.96%	53.09%	52.92%
EBITDA Margin	11.65%	12.15%	10.71%	16.82%	15.02%	15.21%	7.03%	9.29%	27.86%	26.19%
Operating Margin	1.80%	1.01%	-1.88%	9.36%	7.72%	8.48%	2.13%	-1.03%	21.86%	20.07%
EBIT Margin	1.25%	0.75%	-2.11%	9.21%	7.52%	9.10%	1.65%	4.13%	22.48%	20.41%
Profit (Net Income) Margin	-4.94%	-1.31%	-3.26%	7.84%	6.83%	7.98%	2.06%	5.31%	16.63%	13.17%
Tax Burden Percent	178.28%	37.87%	64.93%	83.72%	89.10%	88.08%	128.69%	133.85%	74.07%	64.54%
Interest Burden Percent	-221.96%	-462.76%	238.18%	101.64%	102.01%	99.52%	96.93%	96.16%	99.86%	99.94%
Effective Tax Rate	0.00%	0.00%	0.00%	16.28%	10.90%	11.92%	-28.69%	-33.85%	25.93%	35.46%
Return on Invested Capital (ROIC)	0.93%	0.45%	-1.31%	9.60%	7.99%	9.53%	4.17%	-3.09%	29.40%	24.37%
ROIC Less NNEP Spread (ROIC-NNEP)	-11.38%	-2.78%	-11.51%	9.61%	8.16%	7.56%	7.21%	-27.52%	29.00%	24.17%
Return on Net Nonoperating Assets (RNNOA)	-6.68%	-1.86%	-2.70%	-2.99%	-1.96%	-1.88%	-1.83%	10.48%	-19.22%	-16.10%
Return on Equity (ROE)	-5.76%	-1.41%	-4.01%	6.61%	6.03%	7.65%	2.34%	7.39%	10.17%	8.27%
Cash Return on Invested Capital (CROIC)	16.77%	1.23%	-110.00%	15.25%	6.14%	-9.06%	8.03%	-128.32%	23.53%	0.97%
Operating Return on Assets (OROA)	0.69%	0.38%	-1.50%	6.65%	5.53%	7.03%	1.50%	4.84%	12.81%	11.94%
Return on Assets (ROA)	-2.74%	-0.67%	-2.32%	5.66%	5.03%	6.16%	1.87%	6.24%	9.48%	7.70%
Return on Common Equity (ROCE)	-5.76%	-1.41%	-4.01%	6.61%	6.03%	7.65%	2.34%	7.39%	10.17%	8.27%
Return on Equity Simple (ROE_SIMPLE)	-5.99%	-1.40%	-3.55%	6.38%	5.78%	7.34%	2.28%	5.73%	9.56%	7.76%
Net Operating Profit after Tax (NOPAT)	30	16	-30	103	87	95	38	-18	61	44
NOPAT Margin	1.26%	0.71%	-1.32%	7.84%	6.88%	7.47%	2.74%	-1.38%	16.19%	12.95%
Net Nonoperating Expense Percent (NNEP)	12.30%	3.24%	10.20%	-0.01%	-0.17%	1.97%	-3.03%	24.43%	0.40%	0.20%
Return On Investment Capital (ROIC_SIMPLE)	0.85%	0.43%	-0.80%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	65.38%	67.25%	69.40%	62.66%	63.69%	62.73%	59.28%	67.04%	46.91%	47.08%
SG&A Expenses to Revenue	26.82%	26.86%	26.68%	22.99%	22.34%	21.87%	22.86%	23.38%	23.57%	24.36%
R&D to Revenue	3.72%	3.78%	4.08%	3.61%	3.38%	3.84%	3.78%	3.97%	3.41%	4.60%
Operating Expenses to Revenue	32.82%	31.74%	32.49%	27.98%	28.59%	28.79%	38.59%	33.99%	31.22%	32.85%
Earnings before Interest and Taxes (EBIT)	30	17	-48	121	96	115	23	53	85	70
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	277	274	244	221	191	193	98	120	106	89
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.93	1.13	1.81	3.12	3.00	2.81	3.72	3.63	3.65	3.11
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	3.64	3.54	3.41	4.20	4.17	3.81	3.28
Price to Revenue (P/Rev)	1.59	1.07	1.66	3.83	3.54	3.06	3.36	3.36	6.34	5.27
Price to Earnings (P/E)	0.00	0.00	0.00	48.88	51.80	38.29	163.41	63.34	38.14	40.05
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	2.05%	1.93%	2.61%	0.61%	1.58%	2.62%	2.50%
Enterprise Value to Invested Capital (EV/IC)	1.70	1.08	1.48	4.28	3.71	3.30	4.82	4.37	9.12	7.03
Enterprise Value to Revenue (EV/Rev)	2.13	1.68	2.29	3.40	3.23	2.82	3.10	3.16	5.17	4.17
Enterprise Value to EBITDA (EV/EBITDA)	18.29	13.80	21.36	20.19	21.49	18.57	44.10	34.06	18.57	15.94
Enterprise Value to EBIT (EV/EBIT)	170.59	223.80	0.00	36.87	42.93	31.02	188.08	76.67	23.01	20.45
Enterprise Value to NOPAT (EV/NOPAT)	168.70	237.00	0.00	43.31	46.91	37.81	113.37	0.00	31.94	32.22
Enterprise Value to Operating Cash Flow (EV/OCF)	24.87	22.78	0.00	16.70	18.42	35.08	27.10	26.48	21.82	22.21
Enterprise Value to Free Cash Flow (EV/FCFF)	9.32	87.23	0.00	27.28	60.99	0.00	58.88	0.00	39.90	807.83
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.81	0.77	0.79	0.00	0.02	0.00	0.02	0.05	0.00	0.00
Long-Term Debt to Equity	0.78	0.74	0.78	0.00	0.00	0.00	0.02	0.05	0.00	0.00
Financial Leverage	0.59	0.67	0.23	-0.31	-0.24	-0.25	-0.25	-0.38	-0.66	-0.67
Leverage Ratio	2.10	2.11	1.73	1.17	1.20	1.24	1.25	1.18	1.07	1.07
Compound Leverage Factor	-4.66	-9.77	4.11	1.19	1.22	1.24	1.21	1.14	1.07	1.07
Debt to Total Capital	44.61%	43.48%	44.17%	0.00%	1.72%	0.00%	1.60%	4.41%	0.17%	0.25%
Short-Term Debt to Total Capital	1.44%	1.49%	0.79%	0.00%	1.72%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	43.17%	41.99%	43.38%	0.00%	0.00%	0.00%	1.60%	4.41%	0.17%	0.25%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	55.39%	56.52%	55.83%	100.00%	98.28%	100.00%	98.40%	95.59%	99.83%	99.75%
Debt to EBITDA	5.71	5.95	6.77	0.00	0.14	0.00	0.21	0.46	0.01	0.02
Net Debt to EBITDA	4.59	5.02	5.89	0.00	-2.08	0.00	-3.69	-2.16	-4.20	-4.20
Long-Term Debt to EBITDA	5.52	5.75	6.65	0.00	0.00	0.00	0.21	0.46	0.01	0.02
Debt to NOPAT	52.63	102.25	-55.06	0.00	0.30	0.00	0.54	-3.11	0.02	0.03
Net Debt to NOPAT	42.37	86.30	-47.95	0.00	-4.54	0.00	-9.49	14.58	-7.23	-8.49
Long-Term Debt to NOPAT	50.93	98.75	-54.07	0.00	0.00	0.00	0.54	-3.11	0.02	0.03
Altman Z-Score	2.09	1.63	1.86	13.55	12.36	9.38	10.77	10.79	35.28	25.84
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.59	2.53	2.50	5.13	4.71	3.55	3.72	4.11	14.04	11.85
Quick Ratio	0.33	0.34	0.46	3.35	2.74	1.99	2.24	2.42	12.34	10.19
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	544	43	-2,516	164	67	-90	74	-738	49	1.77
Operating Cash Flow to CapEx	259.49%	201.72%	-69.56%	391.57%	259.53%	104.77%	202.92%	207.34%	447.62%	683.51%
Free Cash Flow to Firm to Interest Expense	5.69	0.46	-37.90	0.00	0.00	-163.81	104.00	-360.65	416.77	45.26
Operating Cash Flow to Interest Expense	2.13	1.75	-0.94	0.00	0.00	185.64	225.97	75.44	762.21	1,646.03
Operating Cash Flow Less CapEx to Interest Expense	1.31	0.88	-2.28	0.00	0.00	8.45	114.61	39.06	591.93	1,405.21
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.56	0.51	0.71	0.72	0.74	0.77	0.91	1.17	0.57	0.59
Accounts Receivable Turnover	13.83	11.79	13.92	11.45	7.79	6.69	7.28	9.82	6.78	7.22
Inventory Turnover	2.41	2.16	3.21	2.73	2.48	2.45	2.77	5.13	3.83	3.99
Fixed Asset Turnover	4.51	3.62	4.13	2.82	2.75	2.85	3.37	5.34	4.74	4.26
Accounts Payable Turnover	10.45	8.30	10.65	10.78	8.08	6.38	8.35	18.66	12.57	12.85
Days Sales Outstanding (DSO)	26.39	30.96	26.22	31.89	46.85	54.56	50.12	37.17	53.80	50.57
Days Inventory Outstanding (DIO)	151.65	168.82	113.76	133.90	147.12	149.06	131.89	71.17	95.26	91.40
Days Payable Outstanding (DPO)	34.93	43.96	34.26	33.85	45.20	57.23	43.69	19.56	29.03	28.42
Cash Conversion Cycle (CCC)	143.11	155.83	105.72	131.93	148.77	146.39	138.32	88.78	120.03	113.55
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,988	3,502	3,530	1,044	1,105	1,085	900	936	215	203
Invested Capital Turnover	0.73	0.64	1.00	1.23	1.16	1.28	1.53	2.25	1.82	1.88
Increase / (Decrease) in Invested Capital	-514	-27	2,486	-61	20	184	-35	720	12	42
Enterprise Value (EV)	5,074	3,787	5,216	4,469	4,103	3,576	4,341	4,089	1,962	1,426
Market Capitalization	3,799	2,408	3,777	5,041	4,500	3,868	4,705	4,348	2,406	1,802
Book Value per Share	$80.27	$87.96	$87.15	$76.09	$71.60	$66.62	$61.67	$59.52	$40.43	$36.30
Tangible Book Value per Share	($8.51)	($9.10)	($14.26)	$65.18	$60.63	$54.88	$54.62	$51.77	$38.71	$34.39
Total Capital	3,548	3,757	3,743	1,616	1,529	1,377	1,284	1,254	661	581
Total Debt	1,583	1,634	1,653	0.00	26	0.00	21	55	1.11	1.48
Total Long-Term Debt	1,532	1,578	1,624	0.00	0.00	0.00	21	55	1.11	1.48
Net Debt	1,274	1,379	1,440	-572	-397	-293	-364	-259	-444	-376
Capital Expenditures (CapEx)	79	82	89	68	86	97	79	74	20	9.39
Debt-free, Cash-free Net Working Capital (DFCFNWC)	628	541	557	262	341	341	296	354	83	85
Debt-free Net Working Capital (DFNWC)	937	795	770	829	752	634	678	654	529	462
Net Working Capital (NWC)	886	739	741	829	725	634	678	654	529	462
Net Nonoperating Expense (NNE)	148	46	44	0.05	0.60	-6.47	9.50	-86	-1.65	-0.73
Net Nonoperating Obligations (NNO)	1,023	1,379	1,440	-572	-397	-293	-364	-263	-445	-377
Total Depreciation and Amortization (D&A)	248	257	292	100	95	77	75	67	20	20
Debt-free, Cash-free Net Working Capital to Revenue	26.37%	23.93%	24.44%	19.89%	26.81%	26.94%	21.12%	27.40%	22.00%	24.88%
Debt-free Net Working Capital to Revenue	39.33%	35.20%	33.79%	62.98%	59.13%	50.05%	48.41%	50.62%	139.33%	135.33%
Net Working Capital to Revenue	37.19%	32.73%	32.48%	62.98%	57.06%	50.05%	48.41%	50.62%	139.33%	135.33%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($4.83)	($1.23)	($3.11)	$4.86	$4.16	$4.90	$1.41	$3.50	$3.90	$2.84
Adjusted Weighted Average Basic Shares Outstanding	24.39M	24.09M	23.87M	21.21M	20.91M	20.63M	20.39M	19.61M	16.17M	15.85M
Adjusted Diluted Earnings per Share	($4.83)	($1.23)	($3.11)	$4.74	$4.02	$4.69	$1.33	$3.29	$3.66	$2.73
Adjusted Weighted Average Diluted Shares Outstanding	24.39M	24.09M	23.87M	21.78M	21.59M	21.55M	21.60M	20.86M	17.25M	16.50M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	24.52M	24.14M	24.00M	23.79M	21.14M	20.77M	20.50M	20.24M	16.34M	16.12M
Normalized Net Operating Profit after Tax (NOPAT)	68	33	-2.50	118	121	124	109	51	73	52
Normalized NOPAT Margin	2.86%	1.48%	-0.11%	8.99%	9.50%	9.78%	7.78%	3.94%	19.33%	15.13%
Pre Tax Income Margin	-2.77%	-3.47%	-5.02%	9.36%	7.67%	9.06%	1.60%	3.97%	22.45%	20.40%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.31	0.18	-0.72	0.00	0.00	209.94	32.56	26.05	722.73	1,788.15
NOPAT to Interest Expense	0.31	0.17	-0.45	0.00	0.00	172.25	54.01	-8.69	520.66	1,134.69
EBIT Less CapEx to Interest Expense	-0.51	-0.69	-2.07	0.00	0.00	32.75	-78.80	-10.33	552.45	1,547.33
NOPAT Less CapEx to Interest Expense	-0.51	-0.70	-1.80	0.00	0.00	-4.95	-57.35	-45.08	350.38	893.87
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-10.19%	-31.53%	-14.65%	8.08%	14.82%	18.45%	21.71%	5.91%	27.32%	3.39%

This table displays calculated financial ratios and metrics derived from ICU Medical's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	6.71%	7.14%	6.47%	8.58%	-0.35%	1.70%	-7.45%	-2.08%	4.70%	69.74%	77.90%
EBITDA Growth	34.62%	76.48%	-17.44%	0.91%	-31.36%	-22.47%	32.91%	-18.61%	120.06%	43.83%	0.78%
EBIT Growth	185.60%	358.08%	-64.09%	242.45%	-242.41%	-792.58%	637.55%	188.97%	121.86%	-106.59%	-109.19%
NOPAT Growth	220.96%	-1,181.62%	-63.96%	178.70%	-213.41%	-5,387.84%	4,993.58%	5,850.00%	122.28%	-100.76%	-101.04%
Net Income Growth	60.79%	-38.96%	-555.69%	-115.48%	-302.27%	-10.37%	154.80%	-32.91%	74.23%	-177.97%	-142.50%
EPS Growth	61.35%	-36.62%	-550.00%	-114.63%	-297.56%	-10.94%	154.55%	-32.26%	74.53%	-170.33%	-138.46%
Operating Cash Flow Growth	12.09%	-55.96%	2.66%	5,659.91%	11.02%	5,434.25%	1,422.78%	97.60%	3,173.40%	-102.07%	-97.07%
Free Cash Flow Firm Growth	477.04%	2,042.43%	302.50%	354.25%	380.17%	100.76%	95.49%	97.47%	98.81%	-3,169.42%	-4,936.96%
Invested Capital Growth	-13.31%	-14.68%	-5.89%	-6.12%	-2.51%	-0.78%	3.57%	2.58%	1.02%	238.05%	219.03%
Revenue Q/Q Growth	-3.99%	6.90%	-1.23%	5.26%	-3.61%	6.24%	0.73%	-3.40%	-1.62%	-3.32%	6.57%
EBITDA Q/Q Growth	-27.21%	31.72%	4.66%	34.15%	-4.59%	-38.38%	27.92%	-8.74%	7.36%	5.64%	-21.67%
EBIT Q/Q Growth	-64.88%	368.90%	56.80%	133.15%	-5.89%	-165.25%	1,395.15%	-86.22%	763.71%	60.70%	-147.45%
NOPAT Q/Q Growth	108.25%	-1,995.82%	7.07%	172.19%	12.54%	-153.31%	728.01%	-70.62%	4,331.98%	52.46%	-872.92%
Net Income Q/Q Growth	35.05%	27.76%	-54.08%	45.77%	-130.19%	-336.90%	172.86%	-1.24%	36.84%	-17.63%	-76.72%
EPS Q/Q Growth	35.05%	28.15%	-53.41%	46.01%	-129.58%	-336.67%	173.17%	0.00%	35.94%	-16.36%	-77.42%
Operating Cash Flow Q/Q Growth	27.70%	11.34%	-55.95%	78.97%	-49.83%	159.57%	2,485.41%	-103.57%	2,510.58%	-174.10%	103.76%
Free Cash Flow Firm Q/Q Growth	15.15%	88.86%	-3.88%	176.07%	327.51%	117.85%	-20.68%	-204.21%	98.84%	-5.89%	32.36%
Invested Capital Q/Q Growth	-0.34%	-10.32%	-0.32%	-2.70%	-1.92%	-1.08%	-0.55%	1.04%	-0.18%	3.25%	-1.49%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	34.75%	36.08%	34.77%	34.78%	32.69%	29.19%	33.24%	35.01%	33.77%	30.27%	31.18%
EBITDA Margin	11.04%	14.56%	11.82%	11.15%	8.75%	8.84%	15.24%	12.00%	12.70%	11.59%	10.61%
Operating Margin	2.13%	5.98%	1.40%	1.29%	-1.88%	-2.07%	4.13%	0.50%	1.65%	-0.04%	-0.08%
EBIT Margin	1.84%	5.03%	1.15%	0.72%	-2.29%	-2.09%	3.40%	0.23%	1.60%	-0.24%	-0.59%
Profit (Net Income) Margin	-2.56%	-3.78%	-5.60%	-3.59%	-6.97%	-2.92%	1.31%	-1.81%	-1.73%	-2.69%	-2.21%
Tax Burden Percent	141.90%	-289.98%	183.97%	109.59%	107.35%	46.75%	-134.89%	43.45%	73.28%	72.44%	61.99%
Interest Burden Percent	-98.03%	25.94%	-265.40%	-453.41%	282.92%	298.88%	-28.53%	-1,817.41%	-146.71%	1,559.78%	608.95%
Effective Tax Rate	0.00%	389.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	1.13%	-12.74%	0.67%	0.60%	-0.85%	-0.93%	1.87%	0.23%	0.76%	-0.03%	-0.05%
ROIC Less NNEP Spread (ROIC-NNEP)	-0.95%	-5.62%	-2.18%	-1.35%	-3.15%	-1.54%	1.25%	-0.61%	-0.44%	-3.57%	-2.95%
Return on Net Nonoperating Assets (RNNOA)	-0.55%	-3.30%	-1.43%	-0.89%	-2.11%	-1.03%	0.87%	-0.41%	-0.28%	-0.84%	-0.73%
Return on Equity (ROE)	0.57%	-16.04%	-0.76%	-0.29%	-2.96%	-1.96%	2.74%	-0.18%	0.48%	-0.86%	-0.78%
Cash Return on Invested Capital (CROIC)	15.71%	16.77%	5.93%	6.46%	2.59%	1.23%	-2.80%	-2.32%	-0.84%	-110.00%	-105.13%
Operating Return on Assets (OROA)	1.05%	2.79%	0.62%	0.38%	-1.18%	-1.06%	1.73%	0.12%	0.80%	-0.17%	-0.38%
Return on Assets (ROA)	-1.46%	-2.10%	-3.02%	-1.89%	-3.59%	-1.48%	0.67%	-0.92%	-0.86%	-1.92%	-1.43%
Return on Common Equity (ROCE)	0.57%	-16.04%	-0.76%	-0.29%	-2.96%	-1.96%	2.74%	-0.18%	0.48%	-0.86%	-0.78%
Return on Equity Simple (ROE_SIMPLE)	-4.71%	0.00%	-5.42%	-3.47%	-2.87%	0.00%	-1.34%	-2.29%	-2.19%	0.00%	-1.93%
Net Operating Profit after Tax (NOPAT)	9.02	-109	5.77	5.38	-7.46	-8.53	16	1.93	6.58	-0.16	-0.33
NOPAT Margin	1.49%	-17.35%	0.98%	0.90%	-1.32%	-1.45%	2.89%	0.35%	1.16%	-0.03%	-0.05%
Net Nonoperating Expense Percent (NNEP)	2.08%	-7.12%	2.84%	1.95%	2.29%	0.61%	0.62%	0.84%	1.20%	3.54%	2.90%
Return On Investment Capital (ROIC_SIMPLE)	0.26%	-3.08%	-	-	-	-0.23%	-	-	-	0.00%	-
Cost of Revenue to Revenue	65.25%	63.92%	65.23%	65.22%	67.31%	70.81%	66.76%	64.99%	66.23%	69.73%	68.82%
SG&A Expenses to Revenue	26.00%	25.22%	27.62%	26.75%	27.82%	26.30%	26.86%	27.47%	26.83%	24.73%	25.67%
R&D to Revenue	3.85%	3.55%	3.57%	3.92%	3.85%	3.81%	3.77%	4.06%	3.48%	4.06%	3.86%
Operating Expenses to Revenue	32.61%	30.10%	33.37%	33.49%	34.57%	31.26%	29.11%	34.51%	32.12%	30.31%	31.26%
Earnings before Interest and Taxes (EBIT)	11	32	6.76	4.31	-13	-12	19	1.26	9.13	-1.38	-3.50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	67	92	70	67	50	52	84	66	72	67	63
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.71	1.93	2.17	1.42	1.25	1.13	1.37	2.03	1.88	1.81	1.79
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.41	1.59	1.90	1.26	1.15	1.07	1.28	1.87	1.72	1.66	1.76
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.56	1.70	1.72	1.26	1.15	1.08	1.22	1.61	1.53	1.48	1.46
Enterprise Value to Revenue (EV/Rev)	1.92	2.13	2.45	1.82	1.75	1.68	1.92	2.50	2.33	2.29	2.45
Enterprise Value to EBITDA (EV/EBITDA)	15.79	18.29	24.13	16.63	15.72	13.80	14.89	21.33	18.95	21.36	22.36
Enterprise Value to EBIT (EV/EBIT)	86.36	170.59	0.00	0.00	0.00	223.80	155.10	1,040.55	1,896.35	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	99.91	168.70	0.00	778.17	2,037.63	237.00	177.19	714.34	888.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	22.20	24.87	22.48	16.52	23.18	22.78	58.93	142.03	0.00	0.00	225.43
Enterprise Value to Free Cash Flow (EV/FCFF)	9.23	9.32	28.13	18.82	43.87	87.23	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.77	0.81	0.78	0.79	0.78	0.77	0.78	0.78	0.78	0.79	0.82
Long-Term Debt to Equity	0.75	0.78	0.75	0.76	0.76	0.74	0.76	0.76	0.77	0.78	0.81
Financial Leverage	0.58	0.59	0.66	0.66	0.67	0.67	0.69	0.67	0.64	0.23	0.25
Leverage Ratio	2.09	2.10	2.09	2.11	2.10	2.11	2.15	2.16	2.15	1.73	1.75
Compound Leverage Factor	-2.05	0.54	-5.56	-9.55	5.95	6.31	-0.61	-39.17	-3.16	26.92	10.63
Debt to Total Capital	43.60%	44.61%	43.79%	44.10%	43.91%	43.48%	43.89%	43.72%	43.95%	44.17%	45.12%
Short-Term Debt to Total Capital	1.36%	1.44%	1.44%	1.44%	1.42%	1.49%	1.39%	1.13%	0.94%	0.79%	0.67%
Long-Term Debt to Total Capital	42.24%	43.17%	42.35%	42.65%	42.49%	41.99%	42.50%	42.60%	43.02%	43.38%	44.44%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	56.40%	55.39%	56.21%	55.91%	56.09%	56.52%	56.11%	56.28%	56.05%	55.83%	54.88%
Debt to EBITDA	5.22	5.71	6.71	6.37	6.43	5.95	5.66	6.11	5.80	6.77	7.39
Net Debt to EBITDA	4.23	4.59	5.40	5.17	5.43	5.02	4.98	5.38	5.01	5.89	6.28
Long-Term Debt to EBITDA	5.05	5.52	6.49	6.16	6.22	5.75	5.49	5.95	5.68	6.65	7.28
Debt to NOPAT	33.00	52.63	-329.92	297.93	833.36	102.25	67.40	204.72	271.80	-55.06	-125.38
Net Debt to NOPAT	26.78	42.37	-265.32	241.83	703.93	86.30	59.23	180.08	234.81	-47.95	-106.54
Long-Term Debt to NOPAT	31.97	50.93	-319.07	288.20	806.33	98.75	65.27	199.44	266.01	-54.07	-123.51
Altman Z-Score	1.99	2.09	2.16	1.76	1.67	1.61	1.76	2.07	1.99	1.89	1.80
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.59	2.59	2.29	2.41	2.61	2.53	2.63	2.57	2.62	2.50	2.45
Quick Ratio	0.84	0.33	0.89	0.89	0.87	0.34	0.78	0.74	0.31	0.46	0.44
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	466	405	214	223	81	19	-106	-88	-29	-2,486	-2,347
Operating Cash Flow to CapEx	352.06%	167.26%	181.33%	425.02%	297.19%	305.07%	164.17%	-8.72%	291.46%	-7.94%	11.19%
Free Cash Flow to Firm to Interest Expense	21.17	17.26	8.69	9.36	3.40	0.77	-4.38	-3.64	-1.28	-123.84	-131.82
Operating Cash Flow to Interest Expense	2.33	1.71	1.46	3.44	1.93	3.74	1.45	-0.06	1.83	-0.09	0.13
Operating Cash Flow Less CapEx to Interest Expense	1.67	0.69	0.66	2.63	1.28	2.51	0.57	-0.76	1.20	-1.16	-1.03
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.57	0.56	0.54	0.53	0.52	0.51	0.51	0.51	0.50	0.71	0.65
Accounts Receivable Turnover	15.31	13.83	13.94	14.68	15.86	11.79	12.01	12.13	13.47	13.92	12.42
Inventory Turnover	2.45	2.41	2.16	2.13	2.12	2.16	2.18	2.28	2.47	3.21	3.04
Fixed Asset Turnover	4.63	4.51	3.89	3.81	3.68	3.62	3.56	3.57	3.55	4.13	3.67
Accounts Payable Turnover	9.44	10.45	9.89	9.65	8.99	8.30	8.50	8.39	8.18	10.65	10.43
Days Sales Outstanding (DSO)	23.84	26.39	26.19	24.87	23.01	30.96	30.40	30.10	27.10	26.22	29.39
Days Inventory Outstanding (DIO)	149.13	151.65	168.64	171.01	172.55	168.82	167.82	160.13	147.92	113.76	120.19
Days Payable Outstanding (DPO)	38.68	34.93	36.92	37.83	40.58	43.96	42.94	43.49	44.62	34.26	35.01
Cash Conversion Cycle (CCC)	134.29	143.11	157.90	158.05	154.98	155.83	155.28	146.74	130.40	105.72	114.57
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,978	2,988	3,332	3,342	3,435	3,502	3,541	3,560	3,523	3,530	3,419
Invested Capital Turnover	0.75	0.73	0.68	0.67	0.65	0.64	0.65	0.65	0.66	1.00	0.91
Increase / (Decrease) in Invested Capital	-457	-514	-209	-218	-88	-27	122	90	35	2,486	2,347
Enterprise Value (EV)	4,651	5,074	5,734	4,198	3,958	3,787	4,315	5,733	5,382	5,216	5,005
Market Capitalization	3,405	3,799	4,451	2,893	2,591	2,408	2,872	4,288	3,959	3,777	3,599
Book Value per Share	$81.07	$80.27	$83.87	$83.63	$85.37	$87.96	$86.94	$87.88	$87.52	$87.15	$84.22
Tangible Book Value per Share	($7.51)	($8.51)	($8.82)	($8.98)	($9.43)	($9.10)	($9.84)	($11.61)	($13.33)	($14.26)	($15.80)
Total Capital	3,524	3,548	3,644	3,645	3,687	3,757	3,740	3,758	3,748	3,743	3,667
Total Debt	1,536	1,583	1,596	1,607	1,619	1,634	1,641	1,643	1,647	1,653	1,655
Total Long-Term Debt	1,489	1,532	1,543	1,555	1,566	1,578	1,589	1,601	1,612	1,624	1,630
Net Debt	1,247	1,274	1,283	1,305	1,367	1,379	1,442	1,445	1,423	1,440	1,406
Capital Expenditures (CapEx)	15	24	20	19	15	30	21	17	14	22	21
Debt-free, Cash-free Net Working Capital (DFCFNWC)	633	628	448	474	533	541	608	606	562	557	488
Debt-free Net Working Capital (DFNWC)	923	937	761	777	785	795	807	803	786	770	735
Net Working Capital (NWC)	875	886	708	724	732	739	755	761	751	741	710
Net Nonoperating Expense (NNE)	24	-85	39	27	32	8.62	8.76	12	16	15	13
Net Nonoperating Obligations (NNO)	990	1,023	1,283	1,305	1,367	1,379	1,442	1,445	1,423	1,440	1,406
Total Depreciation and Amortization (D&A)	56	60	63	62	63	64	66	65	63	68	67
Debt-free, Cash-free Net Working Capital to Revenue	26.16%	26.37%	19.17%	20.57%	23.63%	23.93%	27.05%	26.40%	24.36%	24.44%	23.90%
Debt-free Net Working Capital to Revenue	38.13%	39.33%	32.52%	33.70%	34.77%	35.20%	35.89%	35.02%	34.09%	33.79%	35.99%
Net Working Capital to Revenue	36.15%	37.19%	30.28%	31.42%	32.45%	32.73%	33.58%	33.17%	32.57%	32.48%	34.78%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.63)	($0.97)	($1.35)	($0.88)	($1.63)	($0.71)	$0.30	($0.41)	($0.41)	($0.64)	($0.55)
Adjusted Weighted Average Basic Shares Outstanding	24.54M	24.39M	24.44M	24.39M	24.22M	24.09M	24.13M	24.08M	24.01M	23.87M	23.91M
Adjusted Diluted Earnings per Share	($0.63)	($0.97)	($1.35)	($0.88)	($1.63)	($0.71)	$0.30	($0.41)	($0.41)	($0.64)	($0.55)
Adjusted Weighted Average Diluted Shares Outstanding	24.54M	24.39M	24.44M	24.39M	24.22M	24.09M	24.37M	24.08M	24.01M	23.87M	23.91M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	24.61M	24.52M	24.48M	24.43M	24.37M	24.14M	24.14M	24.14M	24.06M	24.00M	23.98M
Normalized Net Operating Profit after Tax (NOPAT)	21	32	15	17	4.02	-3.81	10	13	14	6.00	6.89
Normalized NOPAT Margin	3.42%	5.12%	2.51%	2.87%	0.71%	-0.65%	1.83%	2.44%	2.43%	1.04%	1.15%
Pre Tax Income Margin	-1.80%	1.30%	-3.04%	-3.27%	-6.49%	-6.24%	-0.97%	-4.16%	-2.35%	-3.71%	-3.56%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.51	1.35	0.27	0.18	-0.55	-0.50	0.78	0.05	0.41	-0.07	-0.20
NOPAT to Interest Expense	0.41	-4.66	0.23	0.23	-0.31	-0.35	0.66	0.08	0.29	-0.01	-0.02
EBIT Less CapEx to Interest Expense	-0.16	0.33	-0.53	-0.63	-1.19	-1.73	-0.11	-0.65	-0.22	-1.14	-1.36
NOPAT Less CapEx to Interest Expense	-0.25	-5.68	-0.57	-0.58	-0.96	-1.58	-0.22	-0.62	-0.34	-1.08	-1.18
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-10.19%	0.00%	0.00%	0.00%	-31.53%	0.00%	0.00%	0.00%	-14.65%	0.00%

Frequently Asked Questions About ICU Medical's Financials

When does ICU Medical's financial year end?

According to the most recent income statement we have on file, ICU Medical's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has ICU Medical's net income changed over the last 9 years?

ICU Medical's net income appears to be on a downward trend, with a most recent value of -$117.69 million in 2024, falling from $44.99 million in 2015. The previous period was -$29.66 million in 2023. Check out ICU Medical's forecast to explore projected trends and price targets.

What is ICU Medical's operating income?

ICU Medical's total operating income in 2024 was $42.96 million, based on the following breakdown:

Total Gross Profit: $824.78 million
Total Operating Expenses: $781.82 million

How has ICU Medical revenue changed over the last 9 years?

Over the last 9 years, ICU Medical's total revenue changed from $341.67 million in 2015 to $2.38 billion in 2024, a change of 597.2%.

How much debt does ICU Medical have?

ICU Medical's total liabilities were at $2.24 billion at the end of 2024, a 0.7% decrease from 2023, and a 4,667.8% increase since 2015.

How has ICU Medical's book value per share changed over the last 9 years?

Over the last 9 years, ICU Medical's book value per share changed from 36.30 in 2015 to 80.27 in 2024, a change of 121.1%.

Related Companies

This page (NASDAQ:ICUI) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ICU Medical (ICUI) Financials

Frequently Asked Questions About ICU Medical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ICU Medical (ICUI) Financials

Annual Income Statements for ICU Medical

Quarterly Income Statements for ICU Medical

Annual Cash Flow Statements for ICU Medical

Quarterly Cash Flow Statements for ICU Medical

Annual Balance Sheets for ICU Medical

Quarterly Balance Sheets for ICU Medical

Annual Metrics And Ratios for ICU Medical

Quarterly Metrics And Ratios for ICU Medical

Frequently Asked Questions About ICU Medical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools